Background: Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited. Objective: To review the concepts and rationale behind targeted agents currently in late-stage clinical testing for patients with CRPC. Methods: Novel targeted therapies in clinical trials were identified from registries. The Medline database was searched for all relevant reports published from 1996 to October 2009. Bibliographies of the retrieved articles and major international meeting abstracts were hand-searched to identify additional studies. Results: Advances in our understanding of the molecular mechanisms underlying prostate cancer (PCa) progression have translated into a variety of treatment approaches. Agents targeting androgen receptor activation and local steroidogenesis, angiogenesis, immunotherapy, apoptosis, chaperone proteins, the insulin-like growth factor (IGF) pathway, RANK ligand, endothelin receptors, and the Src family kinases are entering or have recently completed accrual to phase III trials for patients with CRPC. Conclusions: There has been an increase in the understanding of the mechanisms of progression of CRPC. A number of new agents targeting mechanisms of PCa progression with early promising results are in clinical trials and have the potential to provide novel treatment options for CRPC in the near future.

1.
Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 2008;58:71–96.
2.
Shibata A, Whittemore AS: Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 2001;93:1109–1111.
3.
Balducci L, Beghe C: Cancer and age in the USA. Crit Rev Oncol Hematol 2001;37:137–145.
4.
Kanthoff PW, Halabi S, Conaway M, et al: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of Cancer and Leukemia Group B 9182 Study. J Clin Oncol 1999;17:2506–2513.
5.
Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol 1996;14:1756–1764.
6.
Petrylak D, Tangen CM, Hussian MH, et al: SWOG 99-16: docetaxel and extramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–1520.
7.
Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–1512.
8.
Berthold DR, Pond GR, Soban F, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–245.
9.
Armstrong AJ, George DJ: New drug development in metastatic prostate cancer. Urol Oncol 2008;26:430–437.
10.
Shah RB, Mehra R, Chinniyan AM, et al: Androgen-independent prostate cancer is an heterogeneous group of diseases: lesson from a rapid autopsy program. Cancer Res 2004;64:9209–9216.
11.
Jimenez JA, Kao C, Raikwar S, et al: Current status of antiangiogenic therapy for prostate cancer. Urol Oncol 2006;24:260–268.
12.
George DJ, Halabi S, Shepard TF, et al: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932–1936.
13.
Reese DM, Fratesi P, Corry M, et al: A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate 2001;3:65–70.
14.
Kelly WK, Halabi S, Carducci MA, et al: A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 (abstract). J Clin Oncol 2010;28(suppl):18s.
15.
Di LG, Figg WD, Fossa SD, et al: Combination of bevacizumab and docetaxel in docetaxel pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54:1089–1094.
16.
Lau SC, Rosa DD, Jaison G: Technology evaluaation: VEGF Trap (cancer), Regeneron/Sanofi-Aventis. Curr Opin Mol Ther 2005;7:493–501.
17.
National Institutes of Health: Anfibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). 2010. http://clinicaltrials.gov/ct2/show/NCT00519285.
18.
Verheul HM, HammersH, van Herp K, et al: Vascular endothelial growth factor blocks tumor growth, metastasis formation, and vascular leakage in orthotopic murine renal cancer model. Clin Cancer Res 2007;13:4201–4208.
19.
D’Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082–4088.
20.
Figg WD, Kruger EA, Price DK, et al: Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest News Drugs 2002;20:183–194.
21.
Drake MJ, Robson W, Mehta P, et al: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer 2003;88:822–827.
22.
Dahut WL, Gulley JL, Arlen PM, et al: Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532–2539.
23.
Figg WD, Raje S, Bauer KS, et al: Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 1999;88:121–125.
24.
Dahut WL, Scripture C, Posadas E, et al: A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008;14:209–214.
25.
Aragon-Ching JB, Jain L, Gully JL, et al: Final analysis of phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009;103:1636–1640.
26.
National Institutes of Health: Sorafenib to overcome resistance to systemic chemotherapy in androgen-independent prostate cancer. 2010. http://www.clinicaltrials.gov/show/NCT00414388.
27.
Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148–1159.
28.
Sonpavde PO, Periman D, Bernold D, et al: Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010;21:319–324.
29.
Zurita J, Liu G, Hutson T, et al: Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (abstract). J Clin Oncol 2009;27:15s.
30.
Dror M, Michaelson MM, Regan WK, et al: Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913–920.
31.
Aragon-Ching B, Dahut WL: About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here? Ann Oncol 2010;21:183–184.
32.
Gravis G, Bladou F, Salem N, et al: Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 2008;19:1624–1628.
33.
Gross M, Higano C, Pantuck A, et al: A phase II trial of docetaxel and erlotinib as first line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007;7:142.
34.
Canil CM, Moore MJ, Winquist E, et al: Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23:455–460.
35.
Boccardo F, Rubagotti A, Conti G, et al: Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. Oncology 2008;74:223–228.
36.
Tatarov O, Mitchell TJ, Seywright M, et al: Src family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009;15:3540–3549.
37.
Fizazi K: The role of Src in prostate cancer. Ann Oncol 2007;18:1765–1773.
38.
Yu EY, Wilding G, Posadas E, et al: Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15:7421–7428.
39.
Araujo J, Gallick G, Trudel G, et al: Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer a phase I/II study (CA180-086) (abstract). J Clin Oncol 2009;27:15s.
40.
National Institutes of Health: A randomized double-blind phase III trial comparing docetaxel combined with dasatinib to docetaxel combined to placebo in castration-resistant prostate cancer. http://clinicaltrials.gov/ct2/show/NCT0074497.
41.
Lara PN Jr, Longmate J, Evans CP, et al: A phase II trial of Src-kinase inhibitor AZD0530 in patients with advanced castration resistant prostate cancer: a California Cancer Consortium study. Anticancer Drug 2009;20:179–184.
42.
Sabbatini P, Larson SM, Kremer A, et al: The prognostic significance of extent of disease in bone in patients with androgen independent prostate cancer. J Clin Oncol 1999;17:948–957.
43.
Nelson JB, Hedican SP, George DJ, et al: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944–949.
44.
Nelson J, Bagnato A, Battistini B: The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110–116.
45.
Carducci MA, Jimeno A: Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006;12:6296–6300.
46.
Nelson JB, Love W, Chin JL, et al: Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic hormone-refractory prostate cancer. Cancer 2008;113:2478–2487.
47.
Carducci MA, Saad F, Abrahamsson PA, et al: A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959–1966.
48.
Armstrong AJ, Creel P, Turnbull J: A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14:6270–6276.
49.
National Institutes of Health: Docetaxel and prednisone with or without atrasentan in treating patients with stage IV prostate cancer and bone metastases that did not respond to previous hormone therapy (identifier NCT00134056). 2010. http://www.clinicaltrials.gov.
50.
James ND, Borre M, Zonnenberg B, et al: ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer and bone metastases (abstract). Eur J Cancer 2007;5(suppl):3.
51.
National Institutes of Health: A phase III trial of ZD4054 (zibotentan) (endothelin A antagonist) and docetaxel in metastatic hormone-resistant prostate cancer. 2010. http://clinicaltrials.gov/ct2/show/NCT00617669.
52.
Chen G, Sircar K, Aprikian A, et al: Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006;107:289–298.
53.
Ellis GK, Bone HG, Chlebowski R, et al: Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875–4882.
54.
Bone HG, Bolognese MA, Yuen CK, et al: Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149–2157.
55.
Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580–8587.
56.
Fizazi K, Carducci A, Smith MR, et al: A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer (abstract). J Clin Oncol 2010;28(suppl): 18s.
57.
Getzenberg RH, Light BW, Lapco PE, et al: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50:999–1006.
58.
Beer TM, Eilers KM, Garzotto M, et al: Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21:123–128.
59.
Beer TM, Ryan CV, Venner PM, et al: Double-blinded randomized study of high-dose calcitriol plus docetaxel in androgen-independent prostate cancer: a report from ASCENT Investigators. J Clin Oncol 2007;25:669–674.
60.
Scher HI, Chi KN, De Wit R, et al: Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): results from the phase III ASCENT2 trial (abstract). J Clin Oncol 2010;28:4509.
61.
Samani AA, Yakar S, Le Roith D, et al: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20–47.
62.
Kurmasheva RT, Houghton PJ: IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006;1766:1–22.
63.
Krueckl SL, Sikes RA, Edlund NM, et al: Increased insulin-like growth factor I receptor expression and signalling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64:8620–8629.
64.
Renehan AG, Zwahlen M, Minder C, et al: Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346–1353.
65.
Chan JM, Stampfer MJ, Ma J, et al: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099–1106.
66.
Hellawell GO, Turner GD, Davies DR, et al: Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:294250.
67.
Krueckl SL, Sikes RA, Edlund NM, et al: Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64:8620–8629.
68.
Wu JD, Odman A, Higgins LM, et al: In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11:3065–3074.
69.
National Institutes of Health: A phase 2, randomized, non-comparative, two arm open label, multiple-center study of CP-751871 in combination with docetaxel/prednisone in chemotherapy naive (arm a) and docetaxel/prednisone refractory (arm b) patients with hormone insensitive prostate cancer. http://clinicaltrials.gov/ct2/show/NCT00313781.
70.
National Institutes of Health: Phase 2 single-arm, open-label study of IMC-A12 in asymptomatic, chemotherapy-naïve patients with metastatic androgen independent prostate cancer. 2010. http://clinicaltrials.gov/ct2/show/NCT00520481.
71.
Fizazi K, Sternberg CN, Fitzpatrick JM, et al: Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int 2010;105:748–767.
72.
Danila D, Hellen G, Gignac GA, et al: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053–7058.
73.
Vainas GI: Octreotide in the management of hormone-refractory prostate cancer. Chemotherapy 2001;47:109–126.
74.
Jerkins SA, Kynaston HG, Davies N: Somatostatin analogs in oncology: a look to the future. Chemotherapy 2001;47:162–196.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.